Janos Tanyi

Assistant Professor

University of Pennsylvania
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (3)

Purpose: Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to PARP inhibitors (PARPi) overcomes PARPi resistance in high-grade serous ovarian cancer (HGSOC) cell and mouse models. We present the results of an investigator-initiated study of combination PARPi (olaparib) and ATRi (ceralasertib) in patients with acquired PARPi-resistant HGSOC. Patients and Methods: Eligible patients had recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR)–deficient (HRD) HGSOC and clinically benefited from PARPi (response by imaging/CA-125 or duration of maintenance therapy; > 12 months first-line or > 6 months ≥ second-line) before progression. No intervening chemotherapy was permitted. Patients received olaparib 300 mg twice daily and ceralasertib 160 mg daily on days 1 to 7 of a 28-day cycle. Primary objectives were safety and objective response rate (ORR). Results: Thirteen patients enrolled were evaluable for safety and 12 for efficacy; 62% ( n = 8) had germline BRCA1/2 mutations, 23% ( n = 3) somatic BRCA1/2 mutations, and 15% ( n = 2) tumors with positive HRD assay. Prior PARPi indication was treatment for recurrence (54%, n = 7), second-line maintenance (38%, n = 5) and first-line treatment with carboplatin/paclitaxel (8%, n = 1). There were 6 partial responses yielding an ORR of 50% (95% confidence interval, 0.15–0.72). Median treatment duration was 8 cycles (range 4–23+). Grade (G) 3/4 toxicities were 38% ( n = 5); 15% ( n = 2) G3 anemia, 23% ( n = 3) G3 thrombocytopenia, 8% ( n = 1) G4 neutropenia. Four patients required dose reductions. No patient discontinued treatment due to toxicity. Conclusions: Combination olaparib and ceralasertib is tolerable and shows activity in HR-deficient platinum-sensitive recurrent HGSOC that benefited and then progressed with PARPi as the penultimate regimen. These data suggest that ceralasertib resensitizes PARPi-resistant HGSOCs to olaparib, warranting further investigation.

Year:

2025

Purpose: PARP inhibitors have become the standard-of-care treatment for homologous recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not all HRD tumors respond to PARPi. Biomarkers to predict response are needed. [ 18 F]FluorThanatrace ([ 18 F]FTT) is a PARPi-analog PET radiotracer that noninvasively measures PARP-1 expression. Herein, we evaluate [ 18 F]FTT as a biomarker to predict response to PARPi in patient-derived xenograft (PDX) models and subjects with HRD HGSOC. Experimental Design: In PDX models, [ 18 F]FTT-PET was performed before and after PARPi (olaparib), ataxia-telangiectasia inhibitor (ATRi), or both (PARPi-ATRi). Changes in [ 18 F]FTT were correlated with tumor volume changes. Subjects were imaged with [ 18 F]FTT-PET at baseline and after ∼1 week of PARPi. Changes in [ 18 F]FTT-PET uptake were compared with changes in tumor size (RECISTv1.1), CA-125, and progression-free survival (PFS). Results: A decrease in [ 18 F]FTT tumor uptake after PARPi correlated with response to PARPi, or PARPi-ATRi treatment in PARPi-resistant PDX models ( r = 0.77–0.81). In subjects ( n = 11), percent difference in [ 18 F]FTT-PET after ∼7 days of PARPi compared with baseline correlated with best RECIST response ( P = 0.01), best CA-125 response ( P = 0.033), and PFS ( P = 0.027). All subjects with >50% reduction in [ 18 F]FTT uptake had >6-month PFS and >50% reduction in CA-125. Utilizing only baseline [ 18 F]FTT uptake did not predict such responses. Conclusions: The decline in [ 18 F]FTT uptake shortly after PARPi initiation provides a measure of drug-target engagement and shows promise as a biomarker to guide PARPi therapies in this pilot study. These results support additional preclinical mechanistic and clinical studies in subjects receiving PARPi ± combination therapy. See related commentary by Liu and Zamarin, p. 1384

Year:

2025

Purpose: Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to poly-ADP ribose polymerase inhibitors (PARPi) overcomes PARPi-resistance in high grade serous ovarian cancer (HGSOC) cell and mouse models. We present the results of an investigator-initiated study of combination PARPi(olaparib) and ATRi(ceralasertib) in patients with acquired PARPi-resistant HGSOC. Patients and Methods: Eligible patients had recurrent, platinum-sensitive BRCA1/2 mutated or homologous recombination (HR) deficient HGSOC and clinically benefited from PARPi (response by imaging/CA-125 or duration of maintenance therapy; >12 months 1 st -line or >6 months ≥2 nd -line) before progression. No intervening chemotherapy was permitted. Patients received olaparib 300mg twice daily and ceralasertib 160mg daily on days 1-7 of a 28-day cycle. Primary objectives were safety and objective response rate (ORR). Results: Thirteen patients enrolled were evaluable for safety and 12 for efficacy. 62%(n=8) had germline BRCA1/2 mutations, 23% (n=3) somatic BRCA1/2 mutations, and 15%(n=2) HR-deficient tumors. Prior PARPi indication was treatment for recurrence (54%, n=7), 2nd line-maintenance (38%, n=5), and frontline treatment with carboplatin/paclitaxel (8%, n=1). There were 6 partial responses yielding an ORR of 50% (95% CI:0.15, 0.72). Median treatment duration was 8 cycles (range 4-23+). Grade(G) 3/4 toxicities were 38%(n=5); 15%(n=2) G3 anemia, 23%(n=3) G3 thrombocytopenia, 8% (n=1) G4 neutropenia. Four patients required dose-reductions. No patient discontinued treatment due to toxicity. Conclusion: Combination olaparib and ceralasertib is tolerable and shows activity in HR-deficient platinum-sensitive recurrent HGSOC that benefited and then progressed with PARPi as the penultimate regimen. These data suggest that ceralasertib re-sensitizes PARPi resistant HGSOCs to olaparib, warranting further investigation.

Year:

2024

Collaborators (13)

Gordon Mills

Professor

Oregon Health & Science University

UNITED STATES
View details

Susan Domchek

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Lainie Martin

University of Pennsylvania Perelman School of Medicine

UNITED STATES
View details

Robert Mach

Britton Chance Professor

University of Pennsylvania

UNITED STATES
View details

Fiona Simpkins

-

UNITED STATES
View details

Lilie L. Lin

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

David A. Mankoff

Matthew J Wilson Professor and Research Vice-Chair of Radiology

University of Pennsylvania

UNITED STATES
View details

Payal D. Shah

University of Pennsylvania

UNITED STATES
View details

Drew Torigian

Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Ie-Ming Shih

Professor

Johns Hopkins University

UNITED STATES
View details

Ronny Drapkin

Franklin Payne Professor of Pathology in Obstetrics and Gynecology

University of Pennsylvania

UNITED STATES
View details

Sarah Gitto

Assistant Research Professor

University of Pennsylvania

UNITED STATES
View details

Stephanie Gaillard

Johns Hopkins University

UNITED STATES
View details